Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren's Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction.

IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14018
Ying-Hsuan Tsai, Jeng-Wei Lu, Jou-I Tu, Yuan-Ju Li, Hui-Fu Hsu, Feng-Hao Chang, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu
{"title":"Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren's Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction.","authors":"Ying-Hsuan Tsai, Jeng-Wei Lu, Jou-I Tu, Yuan-Ju Li, Hui-Fu Hsu, Feng-Hao Chang, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.14018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) are chronic autoimmune diseases that often coexist. They share features such as systemic inflammation and multi-organ involvement and typically require long-term immunosuppressive treatment. However, long-term use of immunosuppressants can cause serious side effects, highlighting the need for adjunct therapies. Molecular hydrogen (H<sub>2</sub>) therapy shows anti-inflammatory, antioxidant, and immunomodulatory properties, with potential benefits in liver, lung, and metabolic diseases. This case report examines a patient with overlapping SLE, SS, and interstitial lung disease (ILD), evaluating the effects of molecular hydrogen therapy on fatigue, immune modulation, and cardiac function.</p><p><strong>Case report: </strong>We present the case of a 69-year-old female diagnosed with Sjögren's syndrome, SLE, and ILD. The patient exhibited chronic symptoms, including xerostomia, xerophthalmia, and respiratory distress, for which she had been receiving corticosteroids and immunomodulatory therapy. Given the persistent disease burden and concerns regarding long-term immunosuppressive therapy, molecular hydrogen therapy was introduced as an adjunctive treatment. Over several months, the patient experienced notable clinical improvements, including resolution of xerostomia, insomnia, dyspnea, chest pain, and dizziness. These symptomatic improvements correlated with favorable immunological shifts in T and B cell subsets, enhanced pulmonary imaging findings, and a reduction in inflammatory markers. Additionally, the patient reported a significant decrease in fatigue, allowing corticosteroid tapering and less reliance on nighttime oxygen. Ongoing hydrogen therapy with high-dose vitamin C maintained disease stability and improved quality of life.</p><p><strong>Conclusion: </strong>This case highlights the potential of molecular hydrogen (H<sub>2</sub>) therapy as a safe, effective adjunct in managing overlapping Sjögren's syndrome, SLE, and ILD. H<sub>2</sub> therapy improved immune profiles and stabilized symptoms in a patient unresponsive to standard treatments.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2228-2235"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) are chronic autoimmune diseases that often coexist. They share features such as systemic inflammation and multi-organ involvement and typically require long-term immunosuppressive treatment. However, long-term use of immunosuppressants can cause serious side effects, highlighting the need for adjunct therapies. Molecular hydrogen (H2) therapy shows anti-inflammatory, antioxidant, and immunomodulatory properties, with potential benefits in liver, lung, and metabolic diseases. This case report examines a patient with overlapping SLE, SS, and interstitial lung disease (ILD), evaluating the effects of molecular hydrogen therapy on fatigue, immune modulation, and cardiac function.

Case report: We present the case of a 69-year-old female diagnosed with Sjögren's syndrome, SLE, and ILD. The patient exhibited chronic symptoms, including xerostomia, xerophthalmia, and respiratory distress, for which she had been receiving corticosteroids and immunomodulatory therapy. Given the persistent disease burden and concerns regarding long-term immunosuppressive therapy, molecular hydrogen therapy was introduced as an adjunctive treatment. Over several months, the patient experienced notable clinical improvements, including resolution of xerostomia, insomnia, dyspnea, chest pain, and dizziness. These symptomatic improvements correlated with favorable immunological shifts in T and B cell subsets, enhanced pulmonary imaging findings, and a reduction in inflammatory markers. Additionally, the patient reported a significant decrease in fatigue, allowing corticosteroid tapering and less reliance on nighttime oxygen. Ongoing hydrogen therapy with high-dose vitamin C maintained disease stability and improved quality of life.

Conclusion: This case highlights the potential of molecular hydrogen (H2) therapy as a safe, effective adjunct in managing overlapping Sjögren's syndrome, SLE, and ILD. H2 therapy improved immune profiles and stabilized symptoms in a patient unresponsive to standard treatments.

分子氢作为辅助治疗的合并症Sjögren's综合征,SLE和ILD:一个病例报告的免疫调节和疲劳减轻。
背景/目的:系统性红斑狼疮(SLE)和Sjögren综合征(SS)是一种经常共存的慢性自身免疫性疾病。它们具有全身性炎症和多器官受累等特征,通常需要长期免疫抑制治疗。然而,长期使用免疫抑制剂可引起严重的副作用,强调需要辅助治疗。分子氢(H2)治疗显示出抗炎、抗氧化和免疫调节特性,对肝、肺和代谢性疾病有潜在的益处。本病例报告检查了一例合并SLE、SS和间质性肺疾病(ILD)的患者,评估了分子氢治疗对疲劳、免疫调节和心功能的影响。病例报告:我们提出的情况下,69岁的女性诊断为Sjögren's综合征,SLE和ILD。患者表现出慢性症状,包括口干、干眼和呼吸窘迫,为此她一直接受皮质类固醇和免疫调节治疗。考虑到持续的疾病负担和对长期免疫抑制治疗的担忧,分子氢疗法被引入作为辅助治疗。在几个月的时间里,患者经历了显著的临床改善,包括口干、失眠、呼吸困难、胸痛和头晕的缓解。这些症状的改善与T细胞和B细胞亚群的有利免疫转移、肺部影像学发现的增强以及炎症标志物的减少有关。此外,患者报告疲劳明显减少,允许皮质类固醇逐渐减少,减少对夜间氧气的依赖。持续的高剂量维生素C氢疗法维持了疾病的稳定性并改善了生活质量。结论:该病例强调了分子氢(H2)治疗作为治疗重叠Sjögren综合征、SLE和ILD的安全、有效辅助手段的潜力。H2治疗改善了对标准治疗无反应的患者的免疫状况并稳定了症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
In vivo
In vivo 医学-医学:研究与实验
CiteScore
4.20
自引率
4.30%
发文量
330
审稿时长
3-8 weeks
期刊介绍: IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信